Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.43 |
| ▸ | OGFRL1 | Q5TC84 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | CCND1 | P24385 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL998966 | 0.88 | KMT2A (0.44) | TRPV1MEN1KMT2ATP53 | |
| SCHEMBL998477 | 0.74 | OPRM1 (0.49) | TRPV1OPRM1OGFRL1MEN1KMT2A | |
| SCHEMBL999105 | 0.73 | TP53 (0.64) | LMNATP53 | |
| SCHEMBL2141034 | 0.72 | OPRM1 (0.63) | OPRM1OGFRL1TP53OPRL1CDK4 | |
| SCHEMBL2141401 | 0.71 | OPRM1 (0.62) | OPRM1OGFRL1LMNATP53OPRL1 | |
| SCHEMBL274685 | 0.71 | OPRM1 (0.48) | OPRM1OGFRL1OPRL1CDK4CCND1 | |
| SCHEMBL23058937 | 0.71 | NPC1 (0.48) | TRPV1OPRM1OGFRL1MEN1KMT2A | |
| SCHEMBL23058934 | 0.71 | OPRM1 (0.45) | TRPV1OPRM1OGFRL1MEN1KMT2A | |
| SCHEMBL1000290 | 0.70 | LMNA (0.57) | TRPV1LMNATP53 | |
| SCHEMBL2142415 | 0.70 | OPRM1 (0.68) | OPRM1OGFRL1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1637521-B1 | NOVEL TRICYCLIC HETEROCYCLE COMPOUND | ONO PHARMACEUTICAL CO (JP) | 2013-06-19 | — | — | EP | disclosed |
| US-7872133-B2 | Tricyclic heterocycle compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-01-18 | — | — | US | disclosed |
| US-20060154944-A1 | Novel tricyclic heterocycle compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-07-13 | — | — | US | disclosed |
| EP-1637521-A1 | NOVEL TRICYCLIC HETEROCYCLE COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154944-A1 | Novel tricyclic heterocycle compound | CYP11B1, CYP11B2, HCCS | TRPV1 2437/4885OPRM1 1743/4885OGFRL1 2821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.